OSCR
Oscar Health, Inc.
OSCR has the edge over TRLV overall, supported by stronger fundamentals and lower modeled downside.
TRLV
Trulieve Cannabis Corp.
TRLV offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
TRLV Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Healthy | |
| Strong |
TRLV's cash flow and balance sheet are currently healthy, but its revenue and profitability are under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
TRLV PE Valuation
TRLV has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over TRLV on the outlook, with more favorable revenue expectations.
TRLV Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Decline | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect TRLV's earnings to grow and its profitability to improve, but its revenue to decline. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over TRLV on earnings quality, reporting a profit while its opponent remains loss making.
TRLV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.37 | — |
| Q3 2026 | -$2.30 | -$1.66 |
| Q2 2026 | -$2.44 | -$1.62 |
| Q1 2026 | -$0.41 | +$0.38 |
| Q4 2025 | -$0.58 | +$0.21 |
| Q3 2023 | -$2.62 | -$1.35 |
| Q2 2023 | -$2.91 | -$2.19 |
| Q1 2023 | -$1.23 | -$0.94 |
| Q4 2022 | -$1.06 | -983% |
TRLV is still losing money, but less than at its worst: $2.30 per share over the past year, against $2.91 at its worst in mid-2023.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over TRLV on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
TRLV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $230.2M | -20% |
| Q2 2026 | $271M | -10% |
| Q1 2026 | $286.8M | -3.7% |
| Q4 2025 | $293.1M | -2.7% |
| Q3 2025 | $288.2M | +1.4% |
| Q2 2025 | $302.1M | -0.4% |
| Q1 2025 | $297.8M | 0% |
| Q4 2024 | $301.1M | +4.9% |
TRLV's revenue has slid since its 2022 peak: $230M last quarter, down 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +3.8 points |
| Q2 2026 | -137% | -154 points |
| Q1 2026 | 12% | +1.3 points |
| Q4 2025 | 5.2% | +4.8 points |
| Q3 2025 | 15% | +14 points |
| Q2 2025 | 17% | +1 points |
| Q1 2025 | 11% | -4.3 points |
| Q4 2024 | 0.4% | -9.7 points |
TRLV has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over TRLV on cash flow, with more consistent year-over-year improvement.
TRLV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $45.4M | -30% |
| Q2 2026 | $32.1M | -57% |
| Q1 2026 | $42.2M | +25% |
| Q4 2025 | $55.8M | +$67.6M |
| Q3 2025 | $64.4M | +$71M |
| Q2 2025 | $74.5M | +66% |
| Q1 2025 | $33.9M | -73% |
| Q4 2024 | -$11.8M | -110% |
TRLV still generates free cash flow, though less than at its 2024 peak: $176M over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
TRLV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.1% | +7.9M shares |
| 1 year | +4.9% | +9.3M shares |
| 3 years | +6.2% | +11.7M shares |
| 5 years | +47% | +63.7M shares |
TRLV has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
TRLV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | -0.5x | Net Cash |
| Q3 2025 | -0.3x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | 0.2x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | 0.5x | Very low |
| Q2 2024 | 0.0x | Very low |
TRLV has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
TRLV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.1 | Neutral |
| Stochastic | 59.2 | Neutral |
TRLV's weekly RSI is 56 (neutral) and its Stochastic is 59 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
TRLV PE vs Healthcare Sector
TRLV has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
TRLV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.9 | 2.5% above |
| 20 week MA | $10.4 | 7.7% above |
| 50 week MA | $8.85 | 26% above |
| 100 week MA | $7.06 | 58% above |
| 200 week MA | $7.29 | 53% above |
TRLV has climbed back above all five of its weekly moving averages, and it's now 53% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over TRLV on returns for 2026, with the stronger performance.
TRLV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.8 | $31.9 | +195% |
| 2021 | $31.9 | $26.8 | -16% |
| 2022 | $26.8 | $7.58 | -72% |
| 2023 | $7.58 | $5.21 | -31% |
| 2024 | $5.21 | $4.78 | -8.3% |
| 2025 | $4.78 | $7.89 | +65% |
| 2026 YTD | $7.89 | $11.2 | +41% |
TRLV's yearly returns have swung widely, from +195% in 2020 to −72% in 2022. It's up 41% so far in 2026.